MEDraysintell sees an increasing interest from investors and industry as new technologies and products are being marketed or under development.

LOUVAIN-LA-NEUVE AND LALAYE, BELGIUM AND FRANCE, November 8, 2016 /EINPresswire.com/ -- MEDraysintell covers some of the most exciting healthcare technologies using radiation for diagnosis and treatment. MEDraysintell provides over 1,900 pages of unrivaled intelligence covering nuclear medicine, cyclotrons, proton therapy and brachytherapy. Each report can be customized to specific geographic areas, indications or modalities upon request.

As these markets are rising three times faster than the global healthcare, MEDraysintell sees an increasing interest from investors and industry as new technologies and products are being marketed or under development. The conventional pharmaceutical industry is becoming increasingly interested toward the nuclear medicine, mainly in the radiotherapeutic area. Xofigo (Bayer AG) has already demonstrated its potential as a blockbuster, while Lutathera (Advanced Accelerator Applications S.A.) which will reach the market within a few months will probably even reach higher figures. New radiotherapeutic approaches targeting prostate cancer, non-Hodgkin lymphoma or breast cancer seems to be superior to standard chemotherapies and are only a few years away from being introduced to the market. In parallel investment is targeting proton therapy to develop smaller and cheaper proton therapy systems as well as the industry sees new development stage companies developing new approach to particle acceleration and beam delivery.

MEDraysintell has already supported numerous companies globally helping them to better understand these markets, and welcomes your requests for specific intelligence needs in these areas.

“Nuclear Medicine World Market Report & Directory” is a 990-page report providing an exhaustive description and analysis of over 370 radiopharmaceuticals and radionuclides with a comprehensive profile of more than 170 companies and institutions active in the radiopharmaceuticals industry.

“Cyclotrons used in Nuclear Medicine World Market Report & Directory” is a 350-page report providing an extensive review of all cyclotrons around the world (over 1,200) with an exhaustive profile of the 14 companies active in this market.

“Brachytherapy Market Report & Directory Global” provides in a 340-page document a complete description of the radionuclides and devices used in brachytherapy, and a detailed profile of 62 companies and institutions active in this field around the world.

The fourth edition of the “Proton Therapy World Market Report & Directory” is the most comprehensive evaluation of the proton therapy market dynamics on a world basis. It analyzes both past and future trends to the year 2030, and contains a detailed profile of 26 promoters, manufacturers or developers of proton and carbon therapy equipment.

MEDraysintell reports and directories are becoming the sole trusted sources of intelligence in the radiation healthcare industry. Reports can be customized to specific areas or modalities. Sample pages and complete table of contents are available upon request. MEDraysintell also welcomes your requests for specific intelligence needs in these areas.

About MEDraysintell
Strategic intelligence for the radiation healthcare
Bringing value to Businesses and Investors!

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy.

We offer the most comprehensive set of reports and directories, with over 1,800 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories.

MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 40 years of experience in radiation healthcare. www.medraysintell.com

Paul-Emmanuel Goethals and Richard Zimmermann
MEDraysintell
+32 491 080 968 and +33 6 82 80 06 00
email us here